BG106058A - Modulation of excitable tissue function by peripherally administered erythropoietin - Google Patents
Modulation of excitable tissue function by peripherally administered erythropoietinInfo
- Publication number
- BG106058A BG106058A BG106058A BG10605801A BG106058A BG 106058 A BG106058 A BG 106058A BG 106058 A BG106058 A BG 106058A BG 10605801 A BG10605801 A BG 10605801A BG 106058 A BG106058 A BG 106058A
- Authority
- BG
- Bulgaria
- Prior art keywords
- excitable
- function
- erythropoietin
- tissues
- excitable tissue
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
Methods and compositions are provided for protecting or enhancing excitable tissue function in mammals for synthetic administration of an erythropoietin receptor activity modulator, such as erythropoietin, which signals via an EPO-activated receptor to modulate the function of excitable tissue. Excitable tissues include central neuronal tissues, such as the brain, peripheral neuronal tissues, retina, and heart tissue. Protection of excitable tissues provides treatment of hypoxia, seizure disorders, neurodegenerative diseases, hypoglycemia, and neurotoxin poisoning. Enhancement of the function is useful in learning and memory. The invention is also directed to compositions and methods for facilitating the transport of molecules across endothelial cell tight junction barriers, such as the blood-brain barrier, by association of molecules with an erythropoietin receptor activity modulator, such as an eryhropoietin. 32 claims, 9 figures
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29093899A | 1999-04-13 | 1999-04-13 | |
US54722000A | 2000-04-11 | 2000-04-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
BG106058A true BG106058A (en) | 2002-12-29 |
BG65353B1 BG65353B1 (en) | 2008-03-31 |
Family
ID=26966493
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG106058A BG65353B1 (en) | 1999-04-13 | 2001-10-26 | Pharmaceutical composition containing erythroprotein and use thereof in the production of drugs |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1171147A4 (en) |
JP (1) | JP2003520194A (en) |
KR (2) | KR100883232B1 (en) |
CN (1) | CN1607957B (en) |
AU (1) | AU784550B2 (en) |
BG (1) | BG65353B1 (en) |
BR (1) | BR0009737A (en) |
CA (1) | CA2383940A1 (en) |
CR (1) | CR6501A (en) |
CZ (1) | CZ20013695A3 (en) |
EA (1) | EA004766B1 (en) |
HU (1) | HUP0201598A3 (en) |
IL (2) | IL145895A0 (en) |
IS (1) | IS6104A (en) |
MX (1) | MXPA01010177A (en) |
NO (1) | NO20014991L (en) |
NZ (4) | NZ514690A (en) |
PL (1) | PL352223A1 (en) |
SK (1) | SK14412001A3 (en) |
TR (2) | TR200402194T2 (en) |
WO (1) | WO2000061164A1 (en) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19857609A1 (en) | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Use of erythropoietin for the treatment of human cerebral ischemia |
US6855544B1 (en) | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
US7297680B2 (en) | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
US7604960B2 (en) | 1999-04-15 | 2009-10-20 | Crucell Holland B.V. | Transient protein expression methods |
US8236561B2 (en) | 1999-04-15 | 2012-08-07 | Crucell Holland B.V. | Efficient production of IgA in recombinant mammalian cells |
US7521220B2 (en) | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
US7192759B1 (en) | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
US7527961B2 (en) | 1999-11-26 | 2009-05-05 | Crucell Holland B.V. | Production of vaccines |
WO2002002135A1 (en) | 2000-06-30 | 2002-01-10 | Tokyo Metropolitan Institute Of Gerontology | Preventives and remedies for diseases in association with demyelination |
DE10043457A1 (en) * | 2000-09-04 | 2002-03-28 | Hannelore Ehrenreich | Processes for treating schizophrenia and related psychoses, and using erythropoietin or erythropoietin derivatives to treat schizophrenia and related psychoses |
PA8536201A1 (en) * | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | PROTECTION AND IMPROVEMENT OF CELLS, FABRICS AND ORGANS RESPONDING TO Erythropoietin |
US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
EP1471871B1 (en) * | 2001-02-02 | 2007-05-02 | Ortho-McNeil Pharmaceutical, Inc. | Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin |
US20030118630A1 (en) * | 2001-12-07 | 2003-06-26 | Anthony Cerami | Immune modulation device for use in animals |
BR0213402A (en) | 2001-10-29 | 2004-10-13 | Crucell Holland Bv | Methods for identifying a mammalian cell capable of producing a proteinaceous molecule, for selecting a mammalian cell capable of producing a proteinaceous molecule, for obtaining a mammalian cell from a heterogeneous population of cells, and for producing a proteinaceous molecule, pharmaceutically acceptable composition, recombinantly produced erythropoietin, uses of a mammalian cell, recombinantly produced erythropoietin, and an erythropoietin-like molecule composition, pharmaceutical preparation, method for the preventive and / or therapeutic treatment of a disorder, similar molecule composition to erythropoietin, methods for producing proteinaceous molecules in a mammalian cell, to produce a fraction enriched in a proteinaceous molecule, and to fractionate a mixture containing proteinaceous molecules, fraction, and, uses of a fraction or composition, and erythropoietin recombinantly produced in a mammalian cell |
KR100979025B1 (en) | 2001-12-07 | 2010-08-30 | 크루셀 홀란드 비.브이. | Production of viruses, viral isolates and vaccines |
EP1471930B1 (en) | 2002-01-09 | 2007-04-11 | Crucell Holland B.V. | Use of erythropoietin for the preventive or curative treatment of cardiac failure |
AU2002307635A1 (en) * | 2002-04-19 | 2003-11-03 | Crucell Holland B.V. | Methods and means for producing proteins with predetermined post-translational modifications |
GB0211578D0 (en) * | 2002-05-21 | 2002-06-26 | Univ Belfast | Medicaments |
WO2004003176A2 (en) * | 2002-07-01 | 2004-01-08 | The Kenneth S. Warren Institute, Inc. | Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs |
DE10234192B4 (en) * | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Use of erythropoietin |
US7396913B2 (en) | 2002-10-14 | 2008-07-08 | Abbott Laboratories | Erythropoietin receptor binding antibodies |
EP1633383A4 (en) * | 2003-03-27 | 2008-05-21 | Janssen Pharmaceutica Nv | Use of erythropoietin in stroke recovery |
US7718363B2 (en) | 2003-04-25 | 2010-05-18 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
ATE414144T1 (en) | 2003-05-09 | 2008-11-15 | Crucell Holland Bv | CULTURES OF E1-IMMORALIZED CELLS AND METHOD FOR CULTIVATION THEM TO INCREASE THE PRODUCT YIELDS THEREOF |
DE102004063927A1 (en) * | 2004-01-23 | 2005-12-15 | Epoplus Gmbh Co.Kg | Use of low dose erythropoietin to stimulate endothelial progenitor cells as well as organ regeneration and progression slowing of end organ damage |
AT500929B1 (en) | 2004-11-09 | 2007-03-15 | Medizinische Uni Wien Muw | PHARMACEUTICAL PREPARATION CONTAINING ERYTHROPOIETIN |
AU2006278264B2 (en) | 2005-08-05 | 2012-12-06 | Araim Pharmaceuticals, Inc. | Tissue protective peptides and uses thereof |
US20070072795A1 (en) * | 2005-09-28 | 2007-03-29 | Anton Haselbeck | Treatment of neurodegenerative disorders |
GB0525540D0 (en) * | 2005-12-15 | 2006-01-25 | Isis Innovation | New treatment |
DE102006004008A1 (en) | 2006-01-27 | 2007-08-02 | Hannelore Prof. Dr. Dr. Ehrenreich | Treating or preventing multiple sclerosis comprises administering erythropoietin for periods separated by intervals in which no erythropoietin is administered |
CN101062407A (en) * | 2006-04-29 | 2007-10-31 | 中国科学院上海生命科学研究院 | Function of erythropoietin in the preventing and treating of retinal injury |
US8133860B2 (en) * | 2006-07-20 | 2012-03-13 | Rosalind Franklin University Of Medicine And Science | Facilitation of resuscitation from cardiac arrest by erythropoietin |
CN101610782A (en) * | 2007-01-10 | 2009-12-23 | 爱迪生药物公司 | Use has the compounds for treating respiratory chain disorders of erythropoietin or TPO activity |
WO2009010107A1 (en) | 2007-07-19 | 2009-01-22 | Hannelore Ehrenreich | Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis |
SG10202011946PA (en) | 2008-01-22 | 2020-12-30 | Araim Pharmaceuticals Inc | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
RU2519695C2 (en) * | 2010-07-21 | 2014-06-20 | Олег Ильич Эпштейн | Medication for treating attention deficit disorder and method of treating attention deficit disorder |
CN111066727B (en) * | 2019-12-20 | 2021-08-27 | 中国人民解放军陆军军医大学 | Method for constructing mouse model of action mechanism in permeability of hypoxic blood testis barrier |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6197229A (en) * | 1984-10-18 | 1986-05-15 | Chugai Pharmaceut Co Ltd | Stable erythropoietin preparation |
US5614184A (en) * | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
US5661125A (en) * | 1992-08-06 | 1997-08-26 | Amgen, Inc. | Stable and preserved erythropoietin compositions |
US20020052309A1 (en) * | 1996-09-11 | 2002-05-02 | Athanasius A. Anagnostou | Method of treating endothelial injury |
DE19857609A1 (en) * | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Use of erythropoietin for the treatment of human cerebral ischemia |
-
2000
- 2000-04-13 SK SK1441-2001A patent/SK14412001A3/en not_active Application Discontinuation
- 2000-04-13 CZ CZ20013695A patent/CZ20013695A3/en unknown
- 2000-04-13 MX MXPA01010177A patent/MXPA01010177A/en active IP Right Grant
- 2000-04-13 EP EP00923344A patent/EP1171147A4/en not_active Ceased
- 2000-04-13 PL PL00352223A patent/PL352223A1/en not_active Application Discontinuation
- 2000-04-13 TR TR2004/02194T patent/TR200402194T2/en unknown
- 2000-04-13 KR KR1020017013093A patent/KR100883232B1/en not_active IP Right Cessation
- 2000-04-13 JP JP2000610496A patent/JP2003520194A/en active Pending
- 2000-04-13 AU AU43487/00A patent/AU784550B2/en not_active Expired
- 2000-04-13 IL IL14589500A patent/IL145895A0/en unknown
- 2000-04-13 CA CA002383940A patent/CA2383940A1/en not_active Abandoned
- 2000-04-13 KR KR1020077021154A patent/KR101012932B1/en not_active IP Right Cessation
- 2000-04-13 NZ NZ514690A patent/NZ514690A/en not_active IP Right Cessation
- 2000-04-13 NZ NZ533098A patent/NZ533098A/en not_active IP Right Cessation
- 2000-04-13 NZ NZ560696A patent/NZ560696A/en not_active IP Right Cessation
- 2000-04-13 CN CN008087466A patent/CN1607957B/en not_active Expired - Lifetime
- 2000-04-13 EA EA200101073A patent/EA004766B1/en not_active IP Right Cessation
- 2000-04-13 WO PCT/US2000/010019 patent/WO2000061164A1/en active IP Right Grant
- 2000-04-13 NZ NZ545478A patent/NZ545478A/en not_active IP Right Cessation
- 2000-04-13 HU HU0201598A patent/HUP0201598A3/en unknown
- 2000-04-13 TR TR2001/03785T patent/TR200103785T2/en unknown
- 2000-04-13 BR BR0009737-3A patent/BR0009737A/en not_active Application Discontinuation
-
2001
- 2001-10-11 IL IL145895A patent/IL145895A/en not_active IP Right Cessation
- 2001-10-11 IS IS6104A patent/IS6104A/en unknown
- 2001-10-12 NO NO20014991A patent/NO20014991L/en not_active Application Discontinuation
- 2001-10-26 BG BG106058A patent/BG65353B1/en unknown
- 2001-11-13 CR CR6501A patent/CR6501A/en not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG106058A (en) | Modulation of excitable tissue function by peripherally administered erythropoietin | |
ES2131525T3 (en) | THERAPEUTIC USES OF MELANINE. | |
Goudarzvand et al. | Vitamins E and D3 attenuate demyelination and potentiate remyelination processes of hippocampal formation of rats following local injection of ethidium bromide | |
DE69333775D1 (en) | SYNTHETIC CATALYTIC FREE RADICAL RECIPIENTS, USED AS ANTIOXIDANTS FOR THE PREVENTION AND THERAPY OF DISEASES | |
TR200103469T2 (en) | Prevention and treatment of amyloidogenic disease | |
ATE314067T1 (en) | CANNABINOL-11 ACID DERIVATIVES AS ANTI-INFLAMMATORY AND ANALGESICS | |
CA2223510A1 (en) | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease | |
NO990088L (en) | Pharmaceutical preparations comprising S - (-) - N-propargyl-1-aminoindamine | |
BR9714677A (en) | "3-pyridyl enantiomers and their use as analgesics" | |
ATE280758T1 (en) | AGENTS FOR PROTECTING NERVE CELLS | |
Vin et al. | Neuroprotective effect of resveratrol prophylaxis on experimental retinal ischemic injury | |
EP0616032A3 (en) | Preventive or therapeutic agents for Alzheimer's disease, a screening method for Alzheimer's disease, and human tau-protein kinase. | |
WO2002100836A8 (en) | Compounds, compositions and methods for modulating beta-amyloid production | |
Grandas et al. | Blink reflex recovery cycle in patients with blepharospasm unilaterally treated with botulinum toxin | |
DE68928169D1 (en) | Composition for the treatment of degenerative diseases of the nervous system | |
DE69314586D1 (en) | Medicament composition containing TCF-II | |
WO2001019851A3 (en) | Opaminergic neuronal survival-promoting factors and uses thereof | |
EP1020192A3 (en) | Composition against cellulitis | |
DE69612671D1 (en) | BUTYRATE MEDICINE PREPARATIONS OF LACTIC ACID | |
CA2255748A1 (en) | Uridine-comprising therapeutic active agent for treatment of neurodegenerative disorders | |
DE69736241D1 (en) | NEUROTROPHIC CILIARY FACTOR WITH CHANGED ACTIVITY AREA AGAINST THE WILD TYPE MOLECULE | |
Zhu et al. | The dynamic change and regulation of IGF-1 on axonal regeneration after sciatic nerve transaction | |
Krutmann | III. Immunology of UV-irradiated skin | |
WO1999038967A3 (en) | Recombinant proteins derived from hgf and msp | |
Porreca et al. | Nitric oxide modulates neuropeptide Y regulation of ion transport in mouse ileum |